ITECH Radar of Intentions and Possibilities
A sectoral, conversational and strategic intelligence system on nanotechnology, nanomaterials and nanomedicine applied to health in Ibero-America, for the Ibero-American Institute of Technology (ITECH).
Where the game is moving…
A scientific ecosystem of consolidated excellence but fragmented infrastructure: the region produces world-class nano science, while its capacity to translate that science into treatments, manufacturing and retained talent is eroding faster than it is being rebuilt.
7
Strategic lineaments detected
5
Dominant conversations
3
Windows of possibility
6
Countries with traceable evidence
4
Weak signals to monitor
Six movements redefining the field
Each card condenses a conversational movement backed by multiple signals: not an isolated news item, but a sustained shift in positions, decisions or relationships.
01
Argentina's nano science is hollowing out while growing on paper
Actors: CONICET, Institute of Nanoscience and Nanotechnology (INN-CNEA), the national government, receiving centers in Chile and Brazil
Intent: the State seeks to cut science spending on the premise that the market should fund science; researchers seek to sustain their work by moving institutions or countries
Why it matters: Argentina holds part of the region's historical capacity in nanomedicine for neglected diseases (Chagas, leishmaniasis); its unraveling is not only a national loss.
⚠ Trajectory: accelerating
02
Chile and Brazil become destinations for regional nano talent
Actors: Chilean and Brazilian research centers, Argentine scientists in exodus, national science agencies
Intent: receiving countries seek to capitalize on a talent-capture window without having significantly expanded their own structural funding base
Why it matters: the competition for talent is happening within the region, not only toward the global north — a coordination opportunity that today plays out as bilateral competition.
● Trajectory: emerging movement
03
Artificial intelligence is being built into nanomedicine design
Actors: global pharmaceutical companies, computational biology platforms, academic nanoinformatics groups
Intent: reduce time and cost in designing therapeutic nanoparticles through machine learning, betting that the next wave of nanomedicine will be computationally generated
Why it matters: it is a lineament where Ibero-America still has no articulated position, while global capital is already moving decisively toward it.
● Trajectory: emerging movement
04
Europe consolidates its regulatory framework; Latin America delays
Actors: the European Commission, ECHA/EUON, Latin American regulatory agencies, nano startups in clinical stage
Intent: Europe seeks harmonization and regulatory traceability; Latin American regulatory systems, more heterogeneous, have not yet prioritized a specific nanomaterials-in-health framework
Why it matters: Chilean nano companies have already had to test their developments abroad due to a lack of infrastructure and a clear regulatory framework — the regulatory gap is starting to translate into clinical trials leaving the country.
⚠ Trajectory: widening gap
05
The region has not built lipid nanoparticle manufacturing capacity
Actors: global pharmaceutical industry, mRNA platforms, Latin American public health systems
Intent: global players concentrate manufacturing in North America, Europe and Asia; Brazil emerges as the only relevant regional bet, still nascent
Why it matters: it is a health-sovereignty issue — the post-pandemic lesson about vaccine-platform dependency has not been resolved in applied nanotechnology.
⚠ Trajectory: persistent dependency
06
Ibero-American network cooperation is alive, but underused
Actors: CYTED, the NANODYF network, the NANOMED project (Chile-Panama), CIBER-BBN (Spain), Mexican and Argentine universities
Intent: maintain bridges of scientific cooperation, training and technology transfer among Ibero-American countries, focused on diseases prevalent in the region
Why it matters: soft cooperation infrastructure already exists that could absorb part of the fragmentation crisis, but it operates with limited visibility and scale relative to the size of the challenge.
↑ Trajectory: active, with room to scale
03 · Transformation radar
Seven emerging strategic lineaments
Territories of transformation sustained by multiple signals, actors and decisions — not loose topics. Bar length shows current intensity; the tag shows the dominant time horizon.
01Fragility of the scientific ecosystem
Short term
Funding crisis and talent flight, centered on Argentina.
Intensity: 90%
02Clinical and commercial translation
Short term
From nano science to the patient: bottlenecks in infrastructure, funding and clinical trials.
Intensity: 85%
03Nanomedicine for neglected diseases
Medium term
A regional agenda of its own, against the dominant global oncology agenda.
Intensity: 60%
04AI + nanomedicine convergence
Emerging
Computational design of nanoparticles and nanoinformatics.
Intensity: 55%
05Sovereignty in nanoparticle manufacturing
Medium term
Regional production gap in lipid / mRNA platforms.
Intensity: 50%
06Regulation and governance of nanomaterials
Medium term
Divergence between the consolidated European framework and Latin American fragmentation.
Intensity: 45%
07Ibero-American network cooperation
Structural
CYTED, NANODYF and NANOMED as underused soft infrastructure.
Intensity: 40%
Who is connected to whom — and who still isn't
Nodes group actors by function in the system. Magenta connections mark gaps in articulation: relationships that, if activated, would change the game.
Science / academia
CIBER-BBN (Spain)
CONICET / INN (Argentina)
UNAM (Mexico)
CEDENNA (Chile)
UNQ / FIOCRUZ — neglected diseases
Government / regulation
Government of Argentina (budget)
ECHA / EU (REACH-CLP)
COFEPRIS / ANVISA / ANMAT
Industry / capital
Global pharma (Pfizer, Merck…)
Chilean nano startups
LNP manufacturing in Brazil
Regional cooperation / networks
CYTED / NANODYF
NANOMED project
Existing connections
●—● CIBER-BBN (Spain) ↔ CYTED / NANODYF
●—● CONICET / INN (Argentina) ↔ NANOMED project
●—● UNQ / FIOCRUZ ↔ NANOMED project
●—● CONICET / INN (Argentina) ↔ Government of Argentina
●—● ECHA / EU ↔ Global pharma
●—● CEDENNA (Chile) ↔ Chilean nano startups
Gaps in articulation
●┄● CONICET / INN (Argentina) ↔ Global pharma no capital link
●┄● Chilean nano startups ↔ COFEPRIS / ANVISA / ANMAT no shared regulatory framework
●┄● CYTED / NANODYF ↔ LNP manufacturing in Brazil no science-industry bridge
Science / academia
Government / regulation
Industry / capital
Regional cooperation / networks
Gap in articulation
Five conversations shaping the field
These are not frequent topics: each one brings together multiple actors, positions and intentions in active tension or convergence. Tap each tab to see the detail.
Conversation
Can Latin American nano science survive its own funding ecosystems?
Positions
The Argentine government defends the cuts as a market correction; the scientific community describes them as the dismantling of four decades of installed capacity.
Intentions
The government seeks to reduce public spending under a market-driven framework; researchers seek continuity for their work, inside or outside the country.
Actors
CONICETGovernment of ArgentinaINN-CNEAReceiving universities (Chile, Brazil)
Tension
A roughly 50% budget cut for 2026 vs. more than 5,700 documented science-sector job losses in two years.
Evolution
Accelerating: migration toward Chile and Brazil has gone from anecdote to explicit attraction policy on the part of receiving countries.
Conversation
Nanomedicine for neglected diseases as a distinctive regional banner
Positions
A group of regional researchers argues that Chagas, leishmaniasis and dengue deserve their own nano agenda; the global nanomedicine market remains concentrated in oncology.
Intentions
Build scientific legitimacy and funding capacity in a niche where the region has a real, not just aspirational, comparative advantage.
Actors
CYTED / NANOMEDUNQ (Argentina)FIOCRUZ (Brazil)Chilean and Panamanian universities
Tension
Oncology captures most of the global investment and visibility in nanomedicine, leaving little attention for diseases prevalent in the region.
Evolution
Stable, supported by cooperation networks consolidated over more than a decade (CYTED), but without a recent scale jump.
Conversation
AI-nanomedicine convergence: is Ibero-America keeping pace or falling behind?
Positions
The global narrative assumes nanomedicine design will become increasingly computational; in Ibero-America the conversation is still incipient and scattered.
Intentions
Global players seek to reduce R&D time and cost; regional academic groups seek not to be left out of this methodological wave.
Actors
Global pharmaceutical companiesAI biology platformsAcademic nanoinformatics groups
Tension
Global venture capital flowing into AI-biology startups (rounds in the hundreds of millions of dollars) against regional public funding in contraction.
Evolution
Rapidly expanding globally; in the region, still a weak signal more than a consolidated movement.
Conversation
Regulation: the gap between Europe's consolidated framework and Latin America's void
Positions
Europe already operates with a harmonized nanomaterial definition applied under REACH and CLP; Latin America has no equivalent framework coordinated across countries.
Intentions
European regulators seek traceability and standardized health protection; Latin American regulators, with no specific agenda, leave the gap to case-by-case criteria.
Actors
European Commission / ECHACOFEPRIS, ANVISA, ANMATNano startups in clinical validation
Tension
Chilean nano companies have already had to validate their developments abroad due to a lack of infrastructure and an adequate regulatory framework.
Evolution
The gap is widening: Europe keeps refining its framework while the region has not prioritized the issue on its regulatory agenda.
Conversation
Productive sovereignty: who will manufacture the region's future lipid nanoparticles?
Positions
The global lipid-nanoparticle manufacturing market is concentrated in North America, Europe and Asia; Brazil is flagged as the only significant regional growth projection.
Intentions
Global players prioritize larger-scale markets; Brazil seeks to position itself as a regional hub, leveraging its developing pharmaceutical and biotech industry.
Actors
Global pharmaceutical industryBrazil (only relevant regional bet)Latin American public health systems
Tension
The pandemic-era lesson about external dependency in vaccine platforms has not translated into a regional nano-manufacturing strategy.
Evolution
An incipient movement, with Brazil as the only documented case of positive trajectory; the rest of the region remains dependent.
What each key actor seeks, protects and avoids
Intention hypotheses formulated with epistemic discipline: grounded in observable patterns, not certainties.
CONICET / Institute of Nanoscience and Nanotechnology (Argentina)
Driver · Affected
Seeks
To sustain excellence-level nanomedicine research despite budget contraction.
Protects
Scientific capacity accumulated over more than four decades; communities of young researchers.
Avoids
The total dismantling of programs with international reach (Chagas, cancer, magnetic nanoparticles).
Could
transform
transform
Could reconfigure its alliances toward international cooperation if domestic funding does not recover.
High confidence
Government of Argentina
Regulator · Protector
Seeks
To reduce public science spending under a framework of fiscal discipline and trust in private funding.
Protects
An economic model that prioritizes fiscal balance over state investment in basic science.
Avoids
Bearing the political cost of an explicit dismantling of the scientific system.
Could
transform
transform
Could reconsider specific funding lines if private alliances or visible international pressure emerge.
Medium confidence
CIBER-BBN / NANBIOSIS (Spain)
Driver · Connector
Seeks
To consolidate Spanish nanomedicine as an international reference in bioengineering, biomaterials and advanced therapies.
Protects
Its ICTS infrastructure and a network of more than 400 researchers across more than 100 institutions.
Avoids
Fragmentation of its programs given historically low Spanish investment compared with other European countries.
Could
transform
transform
Could expand its connector role toward Ibero-America if it finds regional counterparts able to co-fund.
Medium confidence
Chilean nano centers and startups (CEDENNA, Nanotec, Cellter)
Driver · Emerging · Affected
Seeks
To transfer nano science into commercial and clinical products with impact on strategic sectors (mining, health).
Protects
An incipient regional leadership position in applied nanoscience.
Avoids
Permanent dependence on clinical validation abroad due to a lack of local infrastructure.
Could
transform
transform
Could become a regional translation hub if the infrastructure and risk-financing gap is resolved.
Medium confidence
CYTED / NANODYF Network / NANOMED Project
Connector · Amplifier
Seeks
To maintain and expand Ibero-American scientific cooperation in nanotechnology applied to health.
Protects
Network infrastructure built over more than a decade, present in at least ten countries.
Avoids
Irrelevance in the face of bilateral funding dynamics competing for the same researchers.
Could
transform
transform
Could scale from a scientific cooperation network into a translation platform if it attracts larger-scale funding.
Medium confidence
Global pharmaceutical industry (Pfizer, Merck, Sanofi, Janssen and similar)
Driver · Amplifier
Seeks
To capture the projected growth of the global nanomedicine market, concentrated in oncology and cardiovascular disease.
Protects
Its dominant position in R&D and investment in high commercial-value nano platforms.
Avoids
Diversifying investment toward smaller commercial markets or diseases, such as those neglected in Ibero-America.
Could
transform
transform
Could open regional alliances if sufficiently attractive regulatory or market-access incentives emerge.
Low confidence
What deserves attention, tracking or action
Activate conversation
Argentina's scientific funding crisis and its regional effect
Derived from a structural lineament with multiple actors, open tension and an associated window of possibility. Requires an active conversation, not just observation.
Track
CYTED/NANODYF calls in nanotechnology applied to health
A stable movement with more than a decade of trajectory; worth monitoring new editions and their funding level.
Understand
AI + nanomedicine convergence
An emerging global signal with no clear translation yet in Ibero-America; requires understanding before any institutional position.
Track
Lipid nanoparticle manufacturing in Brazil
The only regional case with a documented growth trajectory; worth following as a possible scale hub.
Observe
Regulatory movements on nanomaterials in Latin America
Still no concrete decisions from COFEPRIS, ANVISA or ANMAT; observe before anticipating a position.
Activate conversation
Intra-regional nano talent circulation (Argentina-Chile-Brazil)
A tension with a clear window of possibility: coordinate instead of competing. Warrants a conversation convened among countries.
Where actors are converging, where they collide
Convergences
Chile–Panama–CYTED on neglected diseases
Argentina–Spain–Slovenia on magnetic nanoparticles
UNAM–University of Groningen on joint training
NANODYF network: 10 countries, shared outreach agenda
Tensions
Argentina's budget cuts vs. the need to scale regional nano science
Global oncology agenda vs. diseases prevalent in Ibero-America
Mature European regulatory framework vs. Latin American regulatory void
Intra-regional talent competition vs. a joint retention strategy
Core · Case · Care · Crack
Core
What intellectual position might ITECH need to explore?
No institutional stance has been formulated yet. The open question emerging from the evidence: should Ibero-America compete in the global oncology agenda dominated by U.S. and Asian capital, or build its own nano agenda centered on neglected diseases and the sustainability of its own scientific systems?
Case
What is the best frame for understanding the game?
A weak and volatile public-funding model, costly infrastructure concentrated in a few hubs (vivariums, GMP), regulation fragmented country by country, and a talent dynamic where countries in the region compete with each other rather than coordinating a joint strategy against the flight toward the global north.
Care
What human impacts need recognition?
Young researchers taking other jobs to get by while continuing to do research; communities with neglected diseases (Chagas, leishmaniasis, dengue) with no access to the nanotherapies the region itself has developed; startups that have to leave the country to clinically validate what they created there.
Crack
What is separated today that, if connected, would change the game?
Excellence-level basic science (CONICET, CIBER-BBN, UNAM, CEDENNA)
✕ disconnected from ✕
Regional translation capital + harmonized regulatory frameworks + scalable manufacturing
The region does not lack science. It lacks translation infrastructure connecting what it already knows how to do with what it needs to build so that science reaches a patient, a vaccine or a commercially valuable patent.
Three openings not yet consolidated
Window 01
An Ibero-American translation network in nanomedicine for neglected diseases
Opening signal
The NANOMED project (Chile–Panama, CYTED) already connects science with regionally prevalent diseases; Argentina has accumulated decades of nanomedicine research for Chagas and leishmaniasis.
Tension
The global oncology agenda captures most of the capital and media attention, leaving the neglected-disease agenda without a regional-scale vehicle.
Actors
CYTED, CONICET/UNQ, Chilean and Panamanian universities, CIBER-BBN, national health agencies.
Intentions
To cooperate so as not to depend on external funding agendas unrelated to the region's own diseases.
What's separated
Excellence-level science scattered across isolated national programs, with no joint funding and visibility vehicle.
What could connect
Existing CYTED/NANODYF networks + Ibero-American cooperation funds + a convening actor with neutral legitimacy.
Possibility
Consolidate the region's own applied-research agenda, with an identity distinct from the global market, and with the potential to attract funding that today doesn't compete for space in the dominant oncology agenda.
Conditions
Requires a convener with no direct commercial interests and the capacity to mobilize multilateral funds.
Risks
That the initiative stays declarative without sustained funding, as has happened with previous cooperation networks.
Signals to monitor
New CYTED calls in nanomedicine; movements of multilateral health funds toward neglected tropical diseases.
Window 02
A regional strategy for circulating nano talent, instead of bilateral competition
Opening signal
Chile and Brazil are actively attracting Argentine talent; Uruguay and Mexico have their own scientific repatriation programs cited as a reference in 2026.
Tension
Countries in the region compete with each other for the same talent instead of coordinating a joint circulation and return strategy.
Actors
National science agencies (CONICET, CONAHCYT, ANII Uruguay), receiving centers in Chile and Brazil, researchers in mobility.
Intentions
Receiving countries seek to capitalize on the Argentine crisis without necessarily building their own long-term structural capacity.
What's separated
National repatriation and talent-attraction programs that don't communicate with each other or share data or best practices at an Ibero-American scale.
What could connect
The different national programs + an Ibero-American scientific mobility platform in nanotechnology that turns flight into circulation.
Possibility
Turn a net-loss-of-capacity dynamic into a regional circulation system that retains knowledge within Ibero-America, even as people move between countries.
Conditions
Requires political will from countries that today compete with each other, and a framework for mutual recognition of credentials and track records.
Risks
That the diagnosis be perceived as interference in sovereign national science policy.
Signals to monitor
The evolution of CONICET's 2026 budget; new talent-attraction program announcements in Chile, Brazil or Mexico.
Window 03
An Ibero-American observatory on governance and nanotoxicology, before the regulatory gap is resolved unilaterally
Opening signal
Mundo Nano (UNAM) devoted its January–June 2026 issue entirely to nanotoxicology; Europe already has a harmonized nanomaterial definition (REACH/CLP) that Latin America does not replicate in a coordinated way.
Tension
A mature regulatory framework in Europe versus the absence of a harmonized framework in Latin America, which is already causing nano developments to be validated outside their country of origin.
Actors
European Commission/ECHA, Latin American national regulatory agencies (COFEPRIS, ANVISA, ANMAT), academic nanotoxicology groups (UNAM, CIBER-BBN).
Intentions
Academia seeks to place the issue on the public agenda before regulation arrives reactively or is imported without regional adaptation.
What's separated
Technical nanotoxicology knowledge already produced by academia + national regulators who have not yet prioritized the issue + an industry that needs clear rules to invest.
What could connect
Regional scientific evidence + a regulator-academia-industry dialogue space convened by a non-governmental actor with technical credibility.
Possibility
Get ahead with a regulatory agenda of its own, built from regional evidence, instead of belatedly importing frameworks designed for other industrial and health contexts.
Conditions
Requires technical legitimacy recognized simultaneously by regulators in several countries.
Risks
That the topic remains confined to academia without translating into public policy.
Signals to monitor
New Mundo Nano publications; regulatory movements from COFEPRIS, ANVISA or ANMAT on nanomaterials.
What ITECH could do with this reading
Possibilities that emerge directly from the analysis, not a content calendar.
Expert roundtable
Nano science under pressure: sustainability of the Ibero-American scientific ecosystem
What funding model could sustain regional nanomedicine beyond national political cycles?
Policy brief
Toward an Ibero-American regulatory agenda for nanomaterials in health
Which elements of the European framework are adaptable, and which require a regional design of their own?
Research note
Nanomedicine for neglected diseases: a map of Ibero-American capabilities
What regional scientific assets already exist, and what's missing to scale them?
Training program / closed session
Circulating nano talent: from flight to network
How can a scientific mobility mechanism be designed that retains knowledge within the region even as people move?
Collaborative project
Ibero-American observatory of nanotechnology applied to health
What format for a permanent observatory could sustain this kind of sector intelligence beyond a one-off report?
Article / report
AI-nanomedicine convergence: what arriving early or late means for Ibero-America
What minimum investment in nanoinformatics would keep the region from being excluded from this methodological wave?
What's worth doing, with whom
Stage 1
Listen
Researchers in mobility, nano startups facing clinical barriers
Stage 2
Explore
CYTED, NANODYF, academic nanotoxicology networks
Stage 3
Connect
Regional cooperation funds, national regulators
Stage 4
Convene
Roundtable on the sustainability of the scientific ecosystem
Stage 5
Co-create
Regulatory policy brief with academia and industry
Stage 6
Amplify
Specialized media, the Ibero-American scientific community
Stage 7
Influence
Regulatory agencies, multilateral funders
What isn't a trend yet
Special issue of Mundo Nano (UNAM) on nanotoxicology, 2026
Why it might matter: Could anticipate greater regional regulatory attention to the topic.
What would confirm the signal: New academic publications or explicit regulatory movements in the coming months.
Uruguay cited as a model for scientific return (Aug. 2026)
Why it might matter: Could become a reference for other countries in the region facing the Argentine crisis.
What would confirm the signal: Other countries announcing similar programs or explicitly adopting the Uruguayan model.
Trilateral Argentina-Spain-Slovenia collaboration on magnetic nanoparticles
Why it might matter: Shows that scientific networks persist despite the domestic funding crisis.
What would confirm the signal: New joint publications or the network expanding to other countries.
Chilean startups validating nano developments outside the country
Why it might matter: Could be the first symptom of a flight not just of talent but of applied R&D.
What would confirm the signal: More similar cases being documented, or Chile announcing a specific regulatory response.
Trajectories to monitor in the coming months
The evolution of CONICET's 2026 budget and its impact on nanomedicine
New CYTED/NANODYF calls in nanotechnology applied to health
Regulatory movements by COFEPRIS, ANVISA and ANMAT on nanomaterials
Progress in lipid nanoparticle manufacturing in Brazil
Integration of AI and nanoinformatics into Ibero-American academic groups
Evidence traceability
Sources support the analysis; they are not the product. Grouped by lineament.
Clinical and commercial translation in the region
- ACCDiS — "Nanomedicine research takes off in the country" (Chile) — accdis.cl
- RCM Salud — "Nanotechnology: the medicine of the future?" (Chile, CEDENNA) — rcmsalud.com
- SITEPD — Nanoparticles against cancer, Fundect/UFMS, March 2026 (Brazil) — sitepd.org.br
Nanomedicine for neglected diseases
- Revista Summa — "Nanomedicine, an example of cooperation between Chile and Panama" (NANOMED/CYTED project) — revistasumma.com
- Beilstein Journal of Nanotechnology — "When nanomedicines meet tropical diseases" (UNQ, FIOCRUZ, University of York) — ncbi.nlm.nih.gov
- CONICET — "Nanomedicines, in Argentina" (UNQ Nanomedicines Program) — conicet.gov.ar
- CONICET — First school-workshop on Nanotechnology and Cancer (UNSAM) — conicet.gov.ar
AI + nanomedicine convergence
- IntuitionLabs — "AI Biologics Discovery: 2026 Pharma Investment Trends" — intuitionlabs.ai
- Drug Target Review — "AI in drug discovery: predictions for 2026" — drugtargetreview.com
- Springer — "AI in Drug Discovery... Nanomedicine, and Precision Therapeutics" (2026) — link.springer.com
Fragility of the scientific ecosystem and talent flight
- BioBioChile — "We're losing an entire generation: Argentina's scientific crisis triggers a talent exodus to Chile and Brazil" (Apr. 2026) — biobiochile.cl
- Wikipedia — "Fuga de cerebros" (CIICTI data, CONICET 2023–2024, 2026 budget) — es.wikipedia.org
- El Nacional — "From brain drain to talent gain" (Uruguay case, Aug. 2026) — elnacional.com
- Inteligencia Argentina — New biotech and nanomedicine patents, UNL–CONICET (Jun. 2026) — inteligenciaargentina.ar
- INN-CNEA/CONICET — Magnetic nanoparticles, Argentina-Spain-Slovenia collaboration (2026) — inn-cnea.conicet.gov.ar
Sovereignty in lipid nanoparticle / mRNA manufacturing
- ColGlob/Towards Healthcare — Lipid nanoparticle manufacturing market 2026-2034 — colglob.com
- GMInsights — Lipid nanoparticles market, Brazil's growth in LatAm — gminsights.com
- Fortune Business Insights — Global lipid nanoparticles market to 2032 — fortunebusinessinsights.com
Regulation and governance of nanomaterials
- ECHA — "Nanomaterials" (REACH/CLP) — echa.europa.eu
- Mundo Nano UNAM — Special issue "Nanotoxicology. Part I", January-June 2026 — mundonano.unam.mx
- Gaceta UNAM — "In nanomedicine, research translates into concrete benefits" (UNAM-Groningen Symposium, Apr. 2026) — gaceta.unam.mx
Ibero-American network cooperation
- CYTED — List of Ibero-American thematic networks — cyted.org
- CIBER-BBN / NANBIOSIS — Institutional profile — nanomedspain.net
- ISCIII — CIBER-BBN Annual Conference, Tarragona — isciii.es
- CASEIB 2026 — Special session "Nanomedicine: the medicine of the future" (SEIB / CIBER-BBN) — caseib.es